Related Experiment Video
Updated: Dec 30, 2025

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
Long non-coding RNA TP73-AS1 in cancers
Chao-Yang Gong1, Rong Tang2, Kai-Xing Liu1
1The Second Clinical Medical College of Lanzhou University, 82 Cuiying Men, Lanzhou 730030, PR China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou 730000, PR China.
Abstract:
More and more evidence indicates that long non-coding RNAs (lncRNAs), as a kind of non-coding endogenous single-stranded RNA, play an essential role as oncogenes or tumour suppressors in the occurrence and development of human cancers. The tumour protein P73 antisense RNA 1 (TP73-AS1) was initially found to be down-regulated in oligodendroglioma and may act as a non-protein-encoding RNA. Since its discovery, TP73-AS1 has been identified as a carcinogenic regulator of many malignancies. At the same time, the high expression of TP73-AS1 is related to the clinicopathological features of patients with cancer. It also regulates cell proliferation, anti-apoptosis, invasion and metastasis through a variety of potential mechanisms, suggesting that it may be a promising biomarker and therapeutic target for cancer. In this review, we summarize the biological functions, mechanisms, and potential clinical implications of TP73-AS1 dysregulation in tumourigenesis and progression.
Insights
Long non-coding RNAs (lncRNAs) are crucial in cancer. TP73-AS1, a specific lncRNA, acts as a cancer regulator, impacting progression and offering potential as a biomarker and therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- RNA Biology
Background:
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in human cancers, acting as oncogenes or tumor suppressors.
- Tumor protein P73 antisense RNA 1 (TP73-AS1) was initially identified as downregulated in oligodendroglioma.
- TP73-AS1 has since emerged as a significant regulator in various malignancies.
Purpose of the Study:
- To review the biological functions of TP73-AS1 in tumorigenesis.
- To elucidate the mechanisms by which TP73-AS1 influences cancer progression.
- To discuss the potential clinical implications of TP73-AS1 as a biomarker and therapeutic target.
Main Methods:
- Literature review of studies on TP73-AS1.
- Analysis of TP73-AS1 expression and its correlation with clinicopathological features.
- Investigation of TP73-AS1's role in cell proliferation, apoptosis, invasion, and metastasis.
Main Results:
- TP73-AS1 is highly expressed in many cancers and linked to adverse clinicopathological features.
- TP73-AS1 regulates key cancer processes including proliferation, anti-apoptosis, invasion, and metastasis.
- Dysregulation of TP73-AS1 is implicated in the occurrence and progression of human cancers.
Conclusions:
- TP73-AS1 plays a critical role in cancer development and progression.
- TP73-AS1 exhibits potential as a promising biomarker for cancer diagnosis and prognosis.
- Targeting TP73-AS1 represents a potential therapeutic strategy for various cancers.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Non-LTR Retrotransposons
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Abnormal Proliferation
piRNA - Piwi-interacting RNAs
